Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 5/20 | 0.81 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.81 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.81 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722027 | 0.90 | GABRG2 (0.66) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7724642 | 0.89 | GABRA3 (0.77) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL19368517 | 0.89 | GABRA3 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL29711999 | 0.89 | GABRA3 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL8360445 | 0.89 | GABRG2 (0.80) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL8229824 | 0.89 | GABRG2 (0.63) | GABRG2GABRB3GABRA3 | |
| SCHEMBL14217670 | 0.88 | GABRG2 (0.62) | GABRG2GABRB3GABRA3 | |
| SCHEMBL8271852 | 0.87 | GABRG2 (0.62) | GABRG2GABRB3GABRA3 | |
| SCHEMBL7717825 | 0.87 | GABRG2 (0.62) | GABRG2GABRB3GABRA3 | |
| SCHEMBL13524265 | 0.87 | GABRG2 (0.62) | GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4129297-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM Research Foundation, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20210309662-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2021-10-07 | — | — | US | disclosed |
| US-10906909-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200181146-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RESEARCH FOUNDATION, INC. | 2020-06-11 | — | — | US | disclosed |
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2017161370-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RESEACH FOUNDATION, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1925614-A1 | Anxiolytic agents with reduced sedative and ataxic effects | Wisys Technology Foundation, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20200181146-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | GABRG2 15/4885GABRB3 9/4885GABRA3 1/4885 |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-20210309662-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-10906909-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRG2 14/4885GABRB3 8/4885GABRA3 1/4885 |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | CHRNA6, GABRA6, CHRNA5 | GABRG2 24/4885GABRB3 17/4885GABRA3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.